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ABSTRACT
Current prognostic tools for non-muscle invasive bladder cancer (NMIBC) do not 
have enough discriminative capacity to predict the risk of tumour progression. This 
study aimed to identify urinary cell microRNAs that may be useful as non-invasive 
predictive biomarkers of tumour progression in NMIBC patients. To this end, 210 
urine samples from NMIBC patients were included in the study. RNA was extracted 
from urinary cells and expression of 8 microRNAs, previously described by our group, 
was analysed by quantitative PCR. A tumour progression predicting model was 
developed by Cox regression analysis and validated by bootstrapping. Regression 
analysis identified miR-140-5p and miR-92a-3p as independent predictors of tumour 
progression. The risk score derived from the model containing these two microRNAs 
was able to discriminate between two groups with a highly significant different 
probability of tumour progression (HR, 5.204; p<0.001) which was maintained when 
patients were stratified according to tumour risk. The algorithm was also able to 
identify two groups with different cancer-specific survival (HR, 3.879; p=0.021). 
Although the data needs to be externally validated, miRNA analysis in urine appears 
to be a valuable prognostic tool in NMIBC patients.
INTRODUCTION
Non-muscle invasive bladder cancers (NMIBC) 
have a 1- and 5-year disease-progression rate of up to 17% 
and 45%, respectively [1]. The current most important 
clinical prognosticators in NMIBC patients, according 
to the EORTC risk tables, are stage T1, high grade (HG) 
and presence of concomitant carcinoma in situ (CIS) 
[2]. Nevertheless, these prognostic factors do not have 
sufficient discriminative capacity to predict, at the patient 
level, the risk of tumour progression. Progressive patients 
deserve careful attention, particularly because therapeutic 
decisions change when patients are likely to progress. 
Many efforts have been made to develop biomarkers for 
assessing aggressiveness and for predicting the prognosis 
of NMIBC patients (reviewed in [3]), but to date none 
of the identified biomarkers is being used in the clinical 
setting due to their limited value. Thus, there is a clear 
need for accurate and reliable predictive biomarkers that 
can distinguish progressive from non-progressive NMIBC.
In recent years it has become apparent that gene 
expression is controlled post-transcriptionally by 
microRNAs (miRNAs), short (21–23 nt) non-coding 
RNAs which bind to specific mRNAs. Experimental 
work has shown that miRNAs are dysregulated in most 
cancer types, including bladder cancer (BC) [4–7], and 
have demonstrated significant diagnostic and prognostic 
values in different malignancies [8–11]. In the case of BC, 
the assessment of the levels of these aberrantly expressed 
miRNAs in urine samples appears to be a promising 
approach to identify diagnostic and prognostic biomarkers 
in a non-invasive way. Urine is a particular source of such 
biomarkers since tumour cells are in direct contact with 
it, it is collected noninvasively and miRNA have shown 
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high stability and easy detectability in urine [12]. Using a 
case-control design, we have shown that urinary miRNA 
profiles vary significantly between urines from control 
and BC patients and between high and low grade tumours 
[13]. Since we have previously found a urinary miRNA 
signature representative of tumour aggressiveness, we 
decided to explore the hypothesis that urinary miRNAs 
may be useful as predictive biomarkers of progression in 
NMIBC patients. We thus compared the urinary miRNA 
profiles from individuals with NMIBC who progressed 
with those who did not progress. Subsequently, we 
developed a prognostic urinary miRNA signature that was 
further internally cross-validated.
RESULTS
Characteristics of the dataset
A total of 210 consecutive urinary samples from BC 
patients with NMIBC subjected to transurethral resection 
of the bladder (TURB) were included (Table 1). Overall, 
22 (11%) patients developed tumour progression and 42 
patients (20%) died, 10 of them (5%) due to BC, after a 
mean follow up of 47 months. The mean time to tumour 
progression and cancer-specific survival was 19 and 23 
months, respectively.
The clinical classifiers for progression, stage, 
grade, presence of CIS, multiplicity and tumour size were 
analysed in both progressive and non-progressive patients. 
Stage T1 and HG tumours were identified in 44% and 54% 
of non-progressive and in 41% and 68% of progressive 
patients, respectively. Concomitant CIS was found in 18% 
of progressive and non-progressive patients. Multiplicity 
was found in 22% and 68% of non-progressive and 
progressive patients, respectively. A tumour diameter of 
> 3 cm was found in 34 out of 188 (18%) non-progressive 
and 6 out of 22 (27%) progressive patients. Recurrent 
tumours were identified in 59% of progressive and 49% 
of non-progressive patients.
Association of miRNA expression and clinical 
features with progression of NMIBC patients
Among the eight previously reported miRNA [13] 
tested in the present work, miR-187-3p and miR-25-3p 
were excluded from further analyses because expression 
data was not available in >30% of samples (insufficient 
cDNA was available to perform all qPCR reactions). 
Supplementary Table 1 shows the fold change differences 
of the miRNAs between the groups and in relation to 
the previous study on these miRNAs. Univariate Cox 
regression analysis including clinical covariates and 
urinary expression levels of miRNAs identified miR-
140-5p, miR-142-3p, miR-18a-3p and miR-92a-3p as 
predictors of tumour progression (Table 2). Of note, none 
of the clinical covariates were significantly associated with 
progression in our cohort of NMIBC. After including the 
above-mentioned miRNAs in the multivariate stepwise 
regression analysis, urinary expression of miR-140-5p and 
miR-92a-3p were found as independent prognostic factors 
of tumour progression (Table 3).
Development of a miRNA-based prognostic 
classifier for NMIBC patients
A 2-miRNA prognostic classifier was developed 
by combining miR-140-5p and miR-92a-3p expression 
values. A risk score (RS) for tumour progression was 
calculated for each patient according to a mathematical 
algorithm containing miR-140-5p and miR-92a-3p 
expression values. The median value of this RS was 
-0.206 (range -1.469 to 1.621). Thereafter, a receiver-
operating characteristic (ROC) curve analysis of the 
model (Figure 1) allowed the selection of a cut-off 
value of 1.62 to classify patients into a high-risk group 
for tumour progression (20%) and low-risk group for 
tumour progression (80%) with an accuracy of 81% (55% 
sensitivity and 84% specificity). Figure 2 depicts Kaplan-
Meier curves generated using the selected cut-off point. 
As shown, RS generated using miRNA expression values 
was able to discriminate between two groups of NMIBC 
patients with a highly significant different probability 
of tumour progression (HR, 5.21; 95%CI, 2.24-12.06; 
p=0.0001) (Figure 2A). It is important to point out that 
when patients were stratified according to BC risk 
groups, the RS continued to discriminate two subgroups 
of different probability of progression (non-high-risk 
NMIBC group: HR, 9.59; 95%CI, 1.84-50.09, p=0.007 
and high-risk NMIBC group: HR, 3.92; 95%CI, 1.42-
10.81, p=0.008) (Figure 3). Moreover, although it did not 
constitute a primary outcome, accuracy of the RS was also 
evaluated regarding the probability of being a predictor 
of cancer-specific survival. Using the same cut-off point, 
the algorithm was also able to distinguish between two 
groups with significantly different probabilities of cancer-
specific survival (HR 3.88; 95%CI, 1.12-13.44, p=0.033) 
(Figure 2B).
Finally, robustness of the mathematical model 
was evaluated by bootstrapping with 1,000 resamples, 
obtaining a C-index after bootstrapping of 0.7306723.
Target prediction and functional enrichment of 
the two miRNA signature
The DIANA-miRPath miRNA analysis, by using 
the 2 miRNAs of the model, showed several statistically 
significant predicted KEGG terms related to cell cycle, 
TGF-β signalling pathway, MAPK signalling pathway, 
Wnt signalling pathway, p53 signalling pathway, and 
pathways in cancer among others. Consistently, when 
analysing the data by the gene intersection and union 
mode, with the two miRNAs targeting the same gene, 
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common terms appear to be significantly enriched 
such as the p53 signalling pathway, TGF-β signalling 
pathway, cell cycle, and pathways in cancer (Figure 4 and 
Supplementary Figure 1).
DISCUSSION
Prediction of disease progression for patients 
diagnosed with NMIBC is an important clinical challenge. 
The most important clinical classifiers for progression 
currently used, stage T1, HG and presence of CIS [2] 
where unable to predict progression in our cohort of 
patients. Neither, the less distinctive clinical prognostic 
classifiers; recurrence, multiplicity and tumour size, 
could distinguish progressive from non-progressive 
patients. One explanation could be that the vast majority 
of our cohort corresponds to HG NMIBC tumours. This 
fact could minimize the impact of clinicopathological 
features on predicting progression, and precisely confirms 
the critical need for new objective methods to identify 
Table 1: Clinicohistopathologic features of the bladder cancer patients
VARIABLES
Gender_N (%)
  Male 157 (75)
  Female 53 (25)
Age_years
  Mean 71
  Range 37-94
Tumour stage and grade_N (%)1
  Tis 15 (7)
  Ta LG 77 (37)
  Ta LG+CIS 1
  Ta HG 22 (10)
  Ta HG+CIS 3 (1)
  T1 LG 1
  T1 LG+CIS 15 (7)
  T1 HG 59 (28)
  T1 HG+CIS 17 (8)
Tumour focality_N (%)
  Unifocal 108 (51)
  Multifocal 102 (49)
Tumour diameter (%)
  ≤3 cm 170 (81)
  >3 cm 40 (19)
Prior recurrence (%)
  Primary tumours 104 (50)
  Recurrent tumours 106 (50)
BCG treatment (%) 98 (47)
TOTAL 210
1The grade and stage of the tumours were determined according to WHO criteria [38] and TNM classification [39], 
respectively.
Abbreviations: CIS or Tis, Carcinoma in situ; LG, Low grade; HG, High grade; BCG, Bacillus Calmette-Guerin
Oncotarget18241www.impactjournals.com/oncotarget
those NMIBC patients that are likely to progress. Here, 
we show that a 2-miRNA urinary signature is able to 
identify a subgroup of NMIBC patients with high-risk of 
progression, thus providing additional risk stratification 
beyond clinicopathological prognosticators.
We and others have previously provided evidence that 
urinary miRNAs can be used as non-invasive diagnostic 
biomarkers for BC patients [13–17]. Cell-free urine and 
serum have also been used as a source of non-invasive 
diagnostic and prognostic biomarkers of BC [18–20], but 
as far as we could ascertain, this is the first study that has 
evaluated urinary cell miRNAs as prognostic biomarkers of 
BC. The results of this study demonstrate that expression of 
miR-140-5p and miR-92a-3p in urinary cells independently 
predicts tumour progression in NMIBC patients. This 
miRNA signature provides an easy-to-use and reliable 
algorithm to identify a subgroup of patients with a higher 
probability of tumour progression and shorter cancer 
specific survival. An accurate estimation of the progression 
risk would help to identify the most appropriate therapy 
for each individual patient. For instance, patients at high 
risk of progression could benefit from re-TURB, adjuvant 
therapies, more aggressive treatments or more intensive 
surveillance. In addition, the 2-miRNA model maintains 
its prognostic ability when NMIBC patients are stratified 
according to their clinicopathological risk group, thus 
reinforcing the validity of our model. Of special interest 
is the predictive value of the model for progression in the 
subset of non-high risk NMIBC that are supposed to have 
low-intermediate risk of progression. Identification of those 
non-high risk NMIBC patients which are more likely to 
progress may help to change current treatment schedules 
for this particular subset of NMIBC patients, intensifying 
their surveillance schedule.
Table 2: Univariate analysis of predictors of tumour progression
Variable Cut-off level/
categories
HR 95% CI P value
Tumour focality uni vs. multifocal 2.25 0.92-5.52 0.0768
Tumour size ≤3 cm vs. >3 cm 1.69 0.66-4.33 0.2718
BCG treatment no vs yes 1.29 0.56-2.98 0.5546
Stage1 Ta vs. T1 1.06 0.72-1.56 0.7738
Grade1 LG vs. HG 1.85 0.75-4.54 0.1792
Concomitant CIS without CIS vs. CIS 1 0.34-2.95 0.9974
miR-140-5p -4.4 2.89 1.13-7.39 0.0267*
miR-142-3p 1.01 3.09 1.26-7.6 0.0139*
miR-18a-3p -7.02 4.40 1.72-11.29 0.0020*
miR-92a-3p -0.555 5.35 1.81-15.53 0.0025*
miR-125b-5p -1.74 0.60 0.23-1.53 0.2813
miR-204-5p -5.15 0.93 0.39-2.21 0.8612
Results of dichotomous clinical variables are expressed considering category placed in second term as the reference 
category
1The grade and stage of the tumours were determined according to WHO criteria [38] and TNM classification [39], 
respectively.
*Statistically significant
Abbreviations: CIS, Carcinoma in situ; LG, Low grade; HG, High grade; BCG, Bacillus Calmette-Guerin; HR, hazard 
ratio; 95%CI, confidence interval.
Table 3: Independent predictors of tumour progression resulting from multivariate stepwise Cox regression analysis
Variable HR 95% CI P value
miR-140-5p 3.53 1.38-9.06 0.0086*
miR-92a-3p 6.21 2.09-18.45 0.0010*
Abbreviations: HR, hazard ratio; 95%CI, confidence interval.
*Statistically significant
Oncotarget18242www.impactjournals.com/oncotarget
Figure 1: ROC curves for miR-140-5p, miR-92a-3p and the 2-miRNA prognostic classifier based on results obtained by 
quantitative PCR in urinary samples of NMIBC patients. A RS for tumour progression was calculated for each patient according 
to a mathematical algorithm containing miR-140-5p and miR-92a-3p expression values as described in Patients and methods section. In this 
equation, miR-140-5p and miR-92a-3p were introduced as dichotomous variables (miR-140-5p expression ≥-4.4=1; <-4.4=0 and miR-92a-
3p expression ≥-0.555=1; <-0.555=0). At fixed sensitivity of 80%, specificity for miR-140-5p and miR-92a-3p individually and combined 
in the 2-miRNA classifier was 32%, 38% and 59%, respectively.
Figure 2: Kaplan-Meier curves for the two-miRNA prognostic classifier showing. A. time to progression and B. time to 
cancer-specific survival for low-risk (RS<1.62; n=168) and high-risk (RS>1.62; n=42) groups of NMIBC patients. CSM; cancer-specific 
mortality.
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Figure 3: Kaplan-Meier curves for the two-miRNA prognostic classifier showing time to progression in 
clinicopathological groups of risk. A. non high-risk NMIBC (n=77) and B. high-risk NMIBC (n=133) patients. Patients were 
divided within each clinicopathological NMIBC risk group according to their RS (RS<1.62, low-risk of progression; RS>1.62, high-risk 
of progression).
Figure 4: Heatmap of the KEGG pathways enriched in two miRNA target genes. Heatmap from intersection of targeted genes 
(genes targeted by the two miRNAs from the model) is shown. The two miRNAs are involved in multiple common pathways, especially in 
cancer-specific pathways (DIANA-miRpath computes log10 P-values).
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Regarding the genetic markers included in our 
algorithm, miR-140-5p has been previously suggested 
to inhibit the expression of TGF-β and MAPK/ERK 
signalling pathways in several malignancies [21–25]. In 
addition, a recent publication reveals that overexpression 
of miR-140-5p has an inhibitory effect on BC by 
downregulating the expression of the oncogenic isoform 
ΔNp63 of TP63 [26], a key gene localized in region 
3q28 associated with BC risk [27]. In agreement with 
this data, we previously found a statistically significant 
downregulation of miR-140-5p in urinary cells from 
BC patients as well as in high grade BC tumours [13], 
although this statistically significant downregulation is 
not seen in the present cohort of NMIBC progressive 
patients. It is most likely that the different cell types and 
the variable proportion of tumour cells in the urine of each 
subject accounts for this lack of statistically significant 
differences.
Aberrations in miR-92a-3p expression have been 
previously reported in many cancers [28–30], but to our 
knowledge, this is the first time miR-92a-3p has been 
associated with BC. In recent studies, it was observed 
that overexpression of miR-92a-3p can disrupt PI3K/
Akt/mTOR pathway by targeting two negative regulatory 
factors of this pathway, PTEN and PHLPP [29, 31]. 
Different studies have reported that overexpression of 
miR-92a-3p is involved in the development of metastasis 
and correlates with survival in different malignancies 
[32–34]. Our study shows that miR-92a-3p is significantly 
overexpressed in urinary cells of NMIBC progressing 
patients which is in concordance with its role as oncomiR.
KEGG pathway analysis corroborates that the 
2-miRNA signature is biologically meaningful. It shows 
that the target genes of the two miRNA take part in many 
important signalling pathways such as cancer pathways, 
cell cycle, TGF-β pathway and p53 signalling pathway, 
among others. Moreover, it has been reported that several 
of the genes targeted by our miRNAs (e.g. TP63, PTEN) 
[35, 36] play a role in the genetic pathogenesis of BC.
The strengths of this study lie in the fact that it 
includes a cohort of patients attended in a single centre, 
homogeneously treated, with prospective data collection 
and long term follow-up. Furthermore, the use of urine 
samples to obtain the miRNA prognostic signature 
may allow the development of a non-invasive bladder 
cancer prognostic tool with an easy translation into 
clinical practice. However, some limitations should be 
acknowledged. First, banked urine samples were analysed, 
so we cannot calculate the rate of experiment failure due to 
low cellularity of the sample. Nonetheless, our experience 
is that the failure rate is low (~5%) in the case of tumour 
samples [37]. Second, the number of events in the cancer-
specific survival analysis is limited. Thus, this part of 
the results must be taken with care until a validation in a 
cohort with larger number of events is performed. Next, 
because of our interest in magnifying the probability to 
identify reliable prognostic miRNAs, all available samples 
were included in the evaluation set, thus preventing an 
independent validation. To overcome this drawback, we 
strictly ascertained the robustness of the mathematical 
algorithm by bootstrapping, obtaining a high concordance 
index. However, the performance of this miRNA signature 
would be more reliable if validation is performed in an 
independent external data set. Finally, we have evaluated a 
limited number of candidate miRNAs previously included 
in our signatures. Other attractive candidate miRNAs with 
prognostic value in BC are reported in the literature. Thus, 
our study rather than establishing a definitive prognostic 
miRNA expression signature, may contribute to describe 
prognostic miRNAs which warrant further prospective 
evaluation in carefully and specifically designed studies.
In summary, our results showed a 2-miRNA urinary 
signature which significantly predicts progression and 
cancer-specific survival in NMIBC patients, indicating 
that it may be a novel potential biomarker for prognosis 
of NMIBC patients.
MATERIALS AND METHODS
Patients and clinical samples
Under Institutional Review Board approval and 
patients’ informed consent, we prospectively collected 
freshly voided urine samples from BC patients at Hospital 
Clínic of Barcelona, starting January 2008. Urines were 
centrifuged and separated into cellular pellet and supernatant 
prior to storage at -80ºC in a urinary biorepository.
For this study, consecutive available banked cellular 
pellets from urine samples collected between January 
2008 and July 2013 at Hospital Clínic of Barcelona 
were used for analysis. These included 210 samples 
from urothelial cell carcinoma of the bladder patients 
subjected to TURB (Table 1) [38, 39]. The only exclusion 
criterion was the lack of follow-up after TURB. Tumours 
were classified according to their clinicopathological 
risk into two categories: high-risk NMIBC tumours [any 
of the following: T1 tumours, HG tumours, CIS, and 
multiple, recurrent, large (>3 cm) Ta low grade tumours 
(all conditions must present for the last point)] and non 
high-risk NMIBC tumours (all tumours not defined in 
the other category). None of the patients included had an 
upper urinary tract tumour. All patients were followed-
up postoperatively following the EAU guidelines [1]. 
Tumours were considered to be in progression when 
pathological stage or histological grade increasing and/or 
distant metastasis or pathological nodes were developed 
during the follow-up.
RNA extraction
Around 50-100 ml of urine was collected from 
each BC patient the day before theTURB. Urine samples 
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were processed as previously described [40], except 
that collected urines were stored at 4ºC and processed 
within the next 24 hours instead of ice cooled. RNAs 
from the urinary cell pellets were extracted using TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s instructions and quantified with a 
NanoDrop1000 (NanoDrop Technologies, Wilmington, 
DE, USA).
miRNA analysis
A total of 8 key miRNAs (miR-25-3p, miR-18a-3p, 
miR-92a-3p, miR-140-5p, miR-125b-5p, miR-142-3p, 
miR-204-5p and miR-187-3p), previously described by 
our group [13], were selected for examination in urinary 
samples from NMIBC patients by quantitative PCR by 
using miRCURY LNA Universal RT microRNA PCR kit 
(Exiqon, Vedbaek, Denmark), as previously described 
[13]. Briefly, total RNA (100 ng) containing miRNA 
was polyadenylated, and cDNA was synthesized using 
a poly(T) primer with a 3’ degenerate anchor and a 5’ 
universal tag. Then, cDNA was served as a template for 
miRNA RT-qPCR amplification with the specific locked 
nucleic acid (LNA) primers (Supplementary Table 2) and 
SYBR Green master mix. PCR reactions were carried out 
using a Light Cycler 480 instrument. The amplification 
profile was denatured at 95ºC for 10 min followed by 45 
amplification cycles of 95ºC for 10s and 60ºC for 1 min. 
At the end of the PCR cycles, melting curve analyses 
were performed. miR-103-3p and miR-30c-5p were used 
as endogenous controls, as previously described [13, 41].
Statistical analysis
Univariate Cox regression analysis was performed 
on each covariate to examine its influence on tumour 
progression and cancer–specific survival. Thereafter, a 
multivariate forward stepwise Cox regression analysis 
was performed. After establishing the multivariate model, 
a RS for the miRNAs of the model was calculated for each 
patient as the linear combination of the model according 
to the following RS=β1× miR-140-5p +β2× miR-92a-3p. 
RS was subjected to a ROC analysis in order to choose 
the most appropriate threshold for predicting tumour 
progression. Then, Kaplan-Meier curves for tumour 
progression and cancer-specific survival were generated 
using the selected cut-off point and compared according 
to the log-rank test. Statistical significance was established 
at p-value of 0.05. R-software and SPSS v23.0 were used 
for calculations.
Finally, robustness of the mathematical algorithm 
resulting from the multivariate analysis was evaluated 
by bootstrapping with 1,000 resamples. For this purpose, 
validate function from RMS Package was used and the 
optimism-adjusted estimate of concordance index was 
computed (http://CRAN.R-project.org/package=rms).
Pathway enrichment analysis
DIANA-miRPath v3.0 software (http://www.microrna.
gr/miRPathv3) [42] using experimentally validated miRNA 
interactions derived from DIANA-TarBase v7 was used to 
identify targets of the miRNAs composing the prognostic 
signature. Subsequent target enrichment analysis was 
performed in order to discover possible canonical altered 









KEGG; kyoto encyclopedia of genes and genomes
LG; low grade
LNA: locked nucleic acid
miRNA; microRNA
NMIBC; non-muscle invasive bladder cancer
ROC; receiver-operating characteristic
RS; risk score
TURB; transurethral resection of the bladder
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